Amylx Pharmaceuticals Inc vs Broadcom Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Broadcom Inc trades at $421.34 (market cap $1.98T). The key difference: Broadcom Inc is far larger — about 750× Amylx Pharmaceuticals Inc's market cap, and Broadcom Inc pays a 0.62% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | AVGO | |
|---|---|---|
Market Cap | $2.64B | $1.98T |
Sector | Health | Technology |
52-Week High | $24.19 | $481.57 |
52-Week Low | $7.82 | $289.60 |
Enterprise Value | $2.39B | $2.02T |
Dividend Yield | — | 0.62% |
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →